BofA Starts Viridian Therapeutics at Buy
The positive initiation and meaningful target gap are bullish, but the view is based on one analyst's assessment.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The positive initiation and meaningful target gap are bullish, but the view is based on one analyst's assessment.
What happened, with direct paths to the underlying reporting
Bank of America initiated coverage of Viridian Therapeutics with a Buy rating and a $47 target versus a posted price of $30.12.
Target: $47
Posted price: $30.12
Analyst firm: Bank of America Securities
Analyst: Daniel Giraldo
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.